Each year in Australia, our people participate in unique initiatives support both each other and our communities. From Ronald Mcdonald House to the MACA Cancer 200 Ride, we're proud of our ongoing community engagement.

— ABOUT US

Community

Making a difference

Lockton has a long-standing tradition of giving back to the communities where we live and work. Since 2012, we have proudly supported local causes including the MACA Cancer 200 Ride for the Harry Perkins Institute of Medical Research. In 2024, we raised $91,000 to fund critical cancer research, helping families spend more time with their loved ones. With over $500,000 in contributions to cancer research, we're supporting dedicated researchers, scientists, and doctors working tirelessly to fight cancer. Some of the other organisations we support include:

Ronald McDonald House Charities Australiaopens a new windowEmpower Hour by Dress for Successopens a new windowCerebral Palsy Allianceopens a new windowRide for Researchopens a new window
Fast facts

0+

Million raised annually, impacting global communities.

0+

Associates lending a hand

0%

Organic global growth

0

Community Impact Award recipients

0+

Million raised annually, impacting global communities.

Questions? We'll guide you in the right direction.

Ask us about our products, services or anything else on your mind. Our insurance and risk specialists are here to help.

Contact us
Two businesswomen engaged in a discussion at a modern office table. They are collaborating on a project with documents and laptops.

Latest from Lockton

Australia’s trade credit insurance (TCI) market is showing renewed momentum, supported by improved underwriting confidence, increased product availability and a growing recognition of trade credit insurance as a strategic risk management tool.Australia’s Trade Credit Insurance Market Regains Momentum, but with Discipline

Australia’s Trade Credit Insurance Market Regains Momentum, but with Discipline

article
Introduction Australia’s trade credit insurance (TCI) market is showing renewed momentum, supported by improved underwriting confidence, increased product availability and a growing recognition of trade credit insurance as a strategic risk management tool. In ...
Read moreAustralia’s Trade Credit Insurance Market Regains Momentum, but with Discipline

How risk is changing across hotel assets

Australia’s hotel sector remains a compelling investment class, but as assets become more complex, so too does the risk profile that underpins them. Hotel risk does not exist neatly within development, ownership or operations, it spans all three. Decisions made during design and construction can influence how an asset performs operationally and how it is viewed by insurers long after completion. Australia’s hotel sector remains a compelling investment class, but as assets become more complex, so too does the risk profile that underpins them. Hotel risk does not exist neatly within development, ownership or operations, it spans all three. Decisions made during design and construction can influence how an asset performs operationally and how it is viewed by insurers long after completion.

NSW releases new Code of Practice for healthcare and social assistance

NSW is the first state to adopt the Healthcare and Social Assistance Industry Code of Practice. Learn what it means for WHS compliance from 20 February 2026.NSW is the first state to adopt the Healthcare and Social Assistance Industry Code of Practice. Learn what it means for WHS compliance from 20 February 2026.

Re-thinking D&O liability for life sciences companies

Life Sciences state of play In the fast-moving world of medtech, biotech, and pharmaceuticals, directors and executives navigate a landscape defined by scientific complexity, regulatory scrutiny, and heightened stakeholder expectations. These factors have led to a profound shift in how Directors & Officers (D&O) exposure is understood, moving from a narrow insurance consideration to a broader reflection of governance, disclosure, and enterprise risk dynamics. Life Sciences state of play In the fast-moving world of medtech, biotech, and pharmaceuticals, directors and executives navigate a landscape defined by scientific complexity, regulatory scrutiny, and heightened stakeholder expectations. These factors have led to a profound shift in how Directors & Officers (D&O) exposure is understood, moving from a narrow insurance consideration to a broader reflection of governance, disclosure, and enterprise risk dynamics.
See all news and insights